ArticleCanadian respiratory journal2026
DLGAP5 Drives Lung Adenocarcinoma Cell Growth by Promoting Autophagy Activity.
Article in Canadian respiratory journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- DLGAP5 Drives Lung Adenocarcinoma Cell Growth by Promoting Autophagy Activity.Canadian respiratory journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundAutophagy is reported to participate in tumorigenesis and plays a vital role in tumor cell survival. Here, we aimed to elucidate the regulatory mechanism between discs large homolog-associated protein 5 (DLGAP5) and autophagy in lung adenocarcinoma (LUAD) development.
methodsRT-qPCR and western blot methods were utilized to assess DLGAP5 expression. Cell proliferation and apoptosis abilities were monitored utilizing Cell Counting Kit 8 (CCK-8), EdU, and flow cytometry assays. Autophagy-related proteins were quantified using western blot and immunofluorescence analysis. A xenograft tumor model was established to measure tumor growth.
resultsDLGAP5 was significantly overexpressed in LUAD cell lines compared to 16HBE cells, especially in PC-9 and A549 cells. Functional assays highlighted that loss of function of DLGAP5 repressed cell proliferation and triggered apoptosis both in vitro and in vivo, while DLGAP5 overexpression had the opposite effect. After DLGAP5 blockage, the autophagy-related LC3II/I and Beclin1 expressions declined, while p62 expression increased. Moreover, the increased proliferation and autophagy activity and suppressed apoptosis mediated by DLGAP5 overexpression were greatly restrained after 3-MA (an autophagy-specific inhibitor).
conclusionTo sum up, DLGAP5 could contribute to proliferation and impede apoptosis of LUAD cells by activating autophagy activity, suggesting that targeting DLGAP5 might be a promising approach for LUAD treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.